Baxter International Inc.
Financials
Valuation Metrics
Baxter International Inc.'s Market Cap is $14.52B. At end of 2025 it was $9.82B. Ranked #745 of 3,112 in US market (top 24%), #514 of 1,667 on NYSE (top 31%), #47 of 206 in Health Care Equipment & Services (top 23%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $14.52B | US#745/3,112 Sec#47/206 |
| Revenue | $11.47B | US#529/3,112 Sec#33/206 |
| Net Income | $-1.06B | US—/3,112 Sec—/206 |
| Total Assets | $19.79B | US#618/3,112 Sec#29/206 |
| Net Assets | $6.21B | US#608/3,112 Sec#36/206 |
| Employees | 37,500 | US#214/3,112 Sec#26/206 |
| Value | ||
| P/B | 2.34x | US#1,387/3,112 Sec#75/206 |
| P/S | 1.27x | US#826/3,112 Sec#59/206 |
| EV/EBITDA | 29.38x | US#2,163/3,112 Sec#115/206 |
| FCF Yield | 4.67% | US#1,352/3,112 Sec#73/206 |
| Profitability | ||
| ROE | -17.13% | US#2,492/3,112 Sec#148/206 |
| ROA | -5.37% | US#2,533/3,112 Sec#141/206 |
| Op. Margin | -2.39% | US#2,502/3,112 Sec#137/206 |
| Revenue Growth | 5.34% | US#1,710/3,112 Sec#130/206 |
| Earnings Growth | 38.46% | US#652/3,112 Sec#29/206 |
| Financial Health | ||
| Debt Ratio | 219.34% | US#1,876/3,112 Sec#161/206 |
| Total Debt | $9.67B | US#399/3,112 Sec#23/206 |
| FCF | $678M | US#736/3,112 Sec#46/206 |
| Cash | $2.15B | US#396/3,112 Sec#22/206 |
| Current Ratio | 1.95x | US#1,286/3,112 Sec#114/206 |
| Net Debt/EBITDA | 10.02x | US#2,368/3,112 Sec#136/206 |
| Dividend | ||
| Div. Yield | 1.30% | US#1,162/3,112 Sec#24/206 |
| Div. Growth | -41.36% | US—/3,112 Sec—/206 |
| Performance | ||
| 1Y Return | 29.01% | US#1,297/3,112 Sec#84/206 |
| 1M Return | 24.08% | US#87/3,112 Sec#14/206 |
| From 52W High | -6.32% | US#694/3,112 Sec#48/206 |
| 1Y MDD | -49.79% | US#2,394/3,112 Sec#146/206 |
| Trading | ||
| Volume | 8,367,310 shares | US#211/3,112 Sec#6/206 |
| Trading Value | $232M | US#468/3,112 Sec#39/206 |
| Per Share | ||
| EPS | $-1.86 | US—/3,112 Sec—/206 |
| BPS | $11.92 | US#1,667/3,112 Sec#96/206 |
Company Info
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.